Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience

Applied Health Economics and Health Policy

Volumn 13, Issue 1, 2015, Pages 47-59

  Bocquet, François ^a,b,c,d   Paubel, Pascal ^b,c   Fusier, Isabelle ^d   Cordonnier, Anne Laure ^d   Sinègre, Martine ^d   Le Pen, Claude ^a  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; NON PRESCRIPTION DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG MARKETING; EUROPE; FRANCE; GERMANY; ITALY; JAPAN; PATENT; PRESCRIPTION; SPAIN; UNITED KINGDOM; CHEMISTRY; CLASSIFICATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HUMAN; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; DRUG COSTS; ERYTHROPOIETIN; FRANCE; GERMANY; GREAT BRITAIN; HUMANS; ITALY; JAPAN; MODELS, THEORETICAL; NONPRESCRIPTION DRUGS; SPAIN;

EID: 84921918300     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0125-6     Document Type: Article

References (75)

1. Surveying tomorrow’s biopharma landscape—the NASDAQ Biotech Index up close evaluate pharma, June 2012. http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf. Accessed 12 Feb 2014.
2. Befrits G. The case for biosimilars: a payer’s perspective. Generics Biosimilars Initiat J. 2013;2(1):12.
3. Roger SD. Biosimilars: how similar or dissimilar are they? Neprology (Carlton). 2006;11(4):341–6.
4. The global use of medicines: outlook through 2016. IMS Health for Healthcare Informatics Report, July 2012. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf. Accessed 16 Mar 2014.
5. Haustein R, de Millas C, Hoër A, et al. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J. 2012;1(3–4):120–6.
6. Schellekens H. How similar ‘biosimilars’ need to be? Nat Biotechnol. 2004;22(11):1357–9.
7. What you need to know about biosimilar medicinal products: process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. European Commission. Consensus Information Paper, 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf. Accessed 17 Mar 2014.
8. Bocquet F, Paubel P. Les aspects juridiques du développement des médicaments biosimilaires [in French]. Revue de Droit Sanitaire et Social. 2012;1:121–33.
9. Guidelines for the quality, safety and efficacy assurance of follow-on biologics, PFSB/ELD notification no. 0304007, MHLW, 4 March 2009. http://www.pmda.go.jp/english/service/pdf/notifications/PFSB-ELD-0304007.pdf. Accessed 28 Mar 2014.
10. Biosimilar development and regulation in Japan. Generics Biosimilars Initiat J. 2013;2(4):207–8.
11. Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan: key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):181–94.
12. Grabowski H, Long G, Mortimer R. Implementation of the biosimilar pathway: economic and policy issues, Seton hall law review. 2011;41(2). Article 2. http://erepository.law.shu.edu/shlr/vol41/iss2/2. Accessed 10 Mar 2014.
13. Kowalchyk K, Crowley-Weber C. Biosimilars: impact of differences with Hatch-Waxman. Pharm Pat Anal. 2013;2(1):29–37.
14. Aggarwal S. What’s fueling the biotech engine 2009–2010. Nat Biotechnol. 2010;28(11):1165–71.
15. IMSHealth. MIDAS database. La Défense: IMS Health; 2013.
16. Biosimilars: How much entry and price competition will result? Office of Health Economics Report based on the proceedings of an OHE Conference held on 2 June 2009, edited by Mattison N, Mestre-Ferrandiz J, Torse A, Dec. 2010. http://www.ohe.org/publications/article/biosimilars-how-much-entry-and-pricecompetition-will-result-13.cfm. Accessed 28 Jan 2014.
17. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev. 2014;13(2):99–100s.
18. Bocquet F, Paubel P, Fusier I et al. Biosimilar hematopoetic growth factors in the public hospitals of Paris: trade-offs between economic goals and evidence based medicine [abstract no. PCASE5 plus poster]. International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress; 3–7 Nov 2012, Berlin.
19. Power DA. Licensing and prescribing biosimilars in Australia. Generics Biosimilars Initiat J. 2013;2(3):152–4.
20. ® (epoetin alfa), European Medicines Agency (EMA), 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf. Accessed 26 Jan 2014.
21. ® (epoetin alfa). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000725/WC500053680.pdf. Accessed 26 Jan 2014.
22. ® (filgrastim), European Medicines Agency (EMA), 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000917/WC500046528.pdf. Accessed 26 Jan 2014.
23. ® (filgrastim), European Medicines Agency (EMA), 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000825/WC500047793.pdf. Accessed 26 Jan 2014.
24. Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal /Abseamed suspended. Generics Biosimilars Initiative Online; Oct. 2009. http://www.gabionline.net/Biosimilars/News/Safety-study-for-subcutaneous-epoetin-alfa-biosimilar-Binocrit-Epoetin-alfa-Hexal-Abseamed-suspended. Accessed 12 Jan 2014.
25. Schellekens H, Jiscoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24(6):613–4.
26. Hermeling S, Schellekens H, Crommelin DJ, et al. Micelle-associated protein in epoietin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20:1903–7.
27. Bocquet F, Paubel P, Fusier I, et al. To what extent can biosimilars compete with brand name biologics? A EU-5 granulocyte-colony stimulating factors markets analysis. Value Health. 2013;16(7):A455.
28. Chauhan D, Towse A, Mestre-Ferrandiz J. The market for biosimilars: evolution and policy options, OHE Briefing No. 45, Office of Health Economics, London. 2008. http://www.ohe.org/publications/article/the-market-for-biosimilars-evolution-and-policy-options-35.cfm. Accessed 11 Jan 2014.
29. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ. 2007;28(4–5):439–45.
30. Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223–8.
31. Bocquet F, Paubel P, Fusier F. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis. Appl Health Econ Health Policy. 2014;12(3):315–26.
32. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7(5):763–73.
33. Pashos CL, Larholt K, Fraser KA, et al. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Support Care Cancer. 2012;20(1):159–65.
34. WHO Collaborating Centre for Drug Statistics Methodology, 2009. http://www.whocc.no/ddd/definition_and_general_considera. Accessed 21 Jan 2014.
35. Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. 2012;2:13–25.
36. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998;100(1):79–89.
37. The biosimilar name debate. What’s at stake for public health. GaBi J. 2014;3(1):10–2.
38. Eurostat, demography—national data—population, 2013. http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=fr&pcode=tps00001. Accessed 5 Jan 2014.
39. The World Bank, data, population (total), 2013. http://data.worldbank.org/indicator/SP.POP.TOTL. Accessed 5 Jan 2014.
40. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union L 136:34–57. http://eur-lex.europa.eu/en/index.htm. Accessed 29 Jan 2014.
41. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union L 136:1–33. http://eur-lex.europa.eu/en/index.htm. Accessed 29 Jan 2014.
42. WHO National Medicine Price Sources, 2010. http://www.who.int/entity/medicines/areas/access/sources_prices/National_Medicine_Price_Sources.pdf. Accessed 31 Mar 2014.
43. IMS. Biosimilar accessible market: size and biosimilar penetration, prepared for EFPIA-EGA-EuropaBio, April 2012. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_imsstudy_en.pdf. Accessed 25 Feb 2014.
44. Black book—blood feud. The coming battle for the $11 billion global EPO market. European EPO market: less EPO, more competition. In: Bernstein Global Wealth Management; 2006. pp. 107–28.
45. Ian Haydock. Biosimilar EPO and novel antidiabetics lead raft of Japanese approvals. Scrip News. Scrip intelligence; 21 Jan 2010. http://www.scripintelligence.com/researchdevelopment/Biosimilar-EPO-and-novel-antidiabetics-lead-raft-of-Japanese-approvals-186811. Accessed 2 Feb 2014.
46. Japan. Generics and Biosimilars Initiative Online; 2012. http://www.gabionline.net/layout/set/print/content/view/full/1676. Accessed 31 Mar 2014.
47. Bogaert P. et al. Biosimilar regulation: important considerations and global developments. Cross-border Life Sciences Handbook. Practical Law Company. http://www.practicallaw.com/3-500-9862#null. Accessed 3 Feb 2014.
48. Agence nationale de sécurité du médicament et des produits de santé, Répertoire des spécialités pharmaceutiques, 2014 [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/index.php. Accessed 31 Mar 2014.
49. Bocquet F, Paubel P, Fusier I et al. Biosimilar hematopoetic growth factors in the public hospitals of Paris: trade-offs between economic goals and evidence based medicine [abstract no. PCASE5 plus poster]. International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress; 2012 Nov 3–7; Berlin.
50. Moreau A, Demolis P, Cavalié C. Les médicaments biosimilaires - Etat des lieux. ANSM Report, Sep 2013 [in French] http://www.ansm.sante.fr/var/ansm_site/storage/original/application/6187b427efca64d2a15e496ff691158e.pdf. Accessed 3 Feb 2014.
51. L’assurance maladie, Base des médicaments et informations tarifaires, BdMIT, 2014 [in French]. http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI. Accessed 12 Mar 2014.
52. Karouby D, Vallet C, Bocquet F, et al. Comparative study of the cost of erythropoietic factors, original medicines and biosimilars in French care facilities. DSL-005. Eur J Hosp Pharm. 2013;20 Suppl 1:A1–238.
53. Financing of Social Security Act for 2004 of 18 December 2003 [in French], loi no. 2003–1199. J Officiel de la République Française 2003 Dec 19;293:21641.
54. Bensadon AC et al. Pertinence d’une intégration du montant des agents stimulant l’érythropoïèse dans les tarifs de dialyse. Inspection Générale des Affaires Sociales, Jul 2010 [in French]. http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/104000477/0000.pdf. Accessed 4 Apr 2014.
55. Degrassat-Théas A, Bensadon MC, Rieu C. Hospital reimbursement price cap for cancer drugs. The French experience in controlling hospital drug expenditures. Pharmacoeconomics. 2012;30(7):565–73.
56. Menditto E, Cammarota S, Putignano D et al. Consumption of biosimilar drugs in Campania region in the years 2009–2012 [abstract no. PHP25 plus poster]. International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress; 2013 Nov 2–6; Dublin.
57. Walsh K. Biosimilars’ utilization and the role payers do play in driving uptake in Europe: an industry perspective. Biosimilar Medicines 11th European Generic Medicines Association (EGA) International Symposium, April 2013. http://sandoz-biosimilars.com/cs/www.sandoz-biosimilars.com-v3/assets/media/shared/documents/presentations/Ken%20Walsh%20EGA%20Annual%20Meeting%202013.pdf. Accessed 5 Apr 2014.
58. Rovira J, Espín J, García L et al. The impact of biosimilars’ entry in the EU market. Andalusian School of Public Health Report for the European Commission (Directorate-General for Enterprise and Industry), Jan 2011. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf. Accessed 5 Apr 2014.
59. Hurtado P, Vieta A, Espinós B, Badia X. Market access barriers for biosimilars in Spain and Germany: epoetin alfa example. Value Health. 2011;14(7):A336.
60. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health Whitepaper, Dec 2011. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf. Accessed 6 Apr 2014.
61. Godman B. Editorial: health authority perspective on biosimilars. Generics Biosimilars Initiat J. 2013;2(1):10–1.
62. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33–40.
63. Blackstone EA, Fuhr JP. The future of competition in the biologics market. Temple J Sci Technol Environ Law. 2012;31:L.1.
64. Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011;29(1):17–33.
65. Garuoliene` K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–9.
66. Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics. 2010;28(8):649–63.
67. Danzon P, Ketcham J. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, the Netherlands and New Zealand. Cambridge: National Bureau of Economic Research; 2004.
68. Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy. 2007;84(1):14–29.
69. National Institute for Health and Care Excellence, Appraisal Consultation Document - Erythropoietin for anemia induced by cancer treatment, Mar 2010. http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=34940 Accessed 6 Apr 2014.
70. Bernstein Research. Biosimilars: quo vadis—a snapshot of the biosimilar industry halfway through its formation. In: Bernstein Global Wealth Management; 2011. pp. 1–73.
71. National Health Service Commissioning Board, October 2012. http://www.england.nhs.uk/wp-content/uploads/2012/09/fs-ccg-respon.pdf. Accessed 22 Mar 2014.
72. US state legislation on biosimilars substitution. Generics Biosimilars Initiat J. 2013;2(3). doi:10.5639/gabij.2013.0203.040.
73. Kaya J, Feagan BG, Guirguisc. Health Canada/BIOTECanada summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012;40:517–27.
74. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm. 2013;70:2004–17.
75. Financing of Social Security Act for 2014 of 23 December 2013 [in French], Art 47, loi no. 2013–1203. J Officiel de la République Française 2013;298:21034.